Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy

Cell Death and Differentiation

Volumn 16, Issue 11, 2009, Pages 1469-1479

  Alajez, N M ^a,b   Shi, W ^a,b   Hui, A B Y ^a,b   Yue, S ^a   Ng, R ^c   Lo, K W ^d   Bastianutto, C ^a,b   O'Sullivan, B ^b,e   Gullane, P ^a   Liu, F F ^a,b,e  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Rouge Valley Hospital   (Canada)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; HISTONE H2AX; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TROLOX C;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IRRADIATION; MITOCHONDRION; MOLECULAR MECHANICS; NASOPHARYNX CANCER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RAT; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL;

ANIMALS; APOPTOSIS; CHROMANS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; MICE; MICROARRAY ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 70350001754     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.85     Document Type: Article

References (40)

1. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6: 846-856.
2. Marx J. Developmental biology. Combing over the polycomb group proteins. Science 2005; 308: 624-626.
3. Levine SS, Weiss A, Erdjument-Bromage H, Shao Z, Tempst P, Kingston RE. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol 2002; 22: 6070-6078.
4. Lund AH, van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004; 16: 239-246.
5. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423: 302-305.
6. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C et al. The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007; 21: 525-530.
7. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006; 66: 6225-6232.
8. Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007; 110: 380-383.
9. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-1521.
10. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 2002; 62: 4736-4745.
11. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999; 13: 2678-2690.
12. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12-22.
13. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003; 63: 4347-4350.
14. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000; 275: 9390-9395.
15. Leach JK, Van Tuyle G, Lin PS, Schmidt-Ullrich R, Mikkelsen RB. Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/ nitrogen. Cancer Res 2001; 61: 3894-3901.
16. McClain DE, Kalinich JF, Ramakrishnan N. Trolox inhibits apoptosis in irradiated MOLT-4 lymphocytes. FASEB J 1995; 9: 1345-1354.
17. Qin L, Zhang X, Zhang L, Feng Y, Weng GX, Li MZ et al. Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun 2008; 371: 531-535.
18. Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene 2006; 25: 4370-4375.
19. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 2002; 8: 131-137.
20. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123-1136.
21. Dutton A, Woodman CB, Chukwuma MB, Last JI, Wei W, Vockerodt M et al Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 2007; 109: 2597-2603.
22. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005; 11: 1306-1313.
23. Chatoo W, Abdouh M, David J, Champagne MP, Ferreira J, Rodier F et al The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. J Neurosci 2009; 29: 529-542.
24. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423: 255-260.
25. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
26. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006; 66: 6063-6071.
27. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-978.
28. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3 K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008; 22: 436-448.
29. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-1785.
30. Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu J, Ito E et al. Significance of PLK1 regulation by mir-100 in human nasopharyngeal cancer. Int J Cancer (submitted).
31. Shi W, Pataki I, MacMillan C, Pintilie M, Payne D, O'Sullivan B et al Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002; 94: 1997-2006.
32. Makitie AA, MacMillan C, Ho J, Shi W, Lee A, O'Sullivan B et al. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003; 9: 2177-2184.
33. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D et al. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 2006; 12: 5726-5732.
34. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999; 83: 121-126.
35. Busson P, Ganem G, Flores P, Mugneret F, Clausse B, Caillou B et al Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 1988; 42 599-606.
36. Alajez NM, Mocanu JD, Shi W, Chia MC, Breitbach CJ, Hui AB et al. Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma. Clin Cancer Res 2008; 14: 4891-4897.
37. Yip KW, Mao X, Au PY, Hedley DW, Chow S, Dalili S et al. Benzethonium chloride: A novel anticancer agent identified by using a cell-based small molecule screen. Clin Cancer Res 2006; 12: 5557-5569.
38. Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 2007; 13: 1490-1495.
39. Li JH, Shi W, Chia M, Sanchez-Sweatman O, Siatskas C, Huang D et al Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol Ther 2003; 8: 964-973.
40. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.